miRNA Details
miRNA General Information | |||||
---|---|---|---|---|---|
miRNA Mature ID | hsa-miR-29a-3p | ||||
miRNA Stemloop AC | MI0000087 | ||||
miRNA Stemloop ID | hsa-mir-29a | ||||
Sequence | uagcaccaucugaaaucgguua | ||||
TTD Target(s) Regulated by This miRNA | HMG-CoA reductase (HMGCR) | Successful Target | Target Info | [1] | |
Matrix metalloproteinase-2 (MMP-2) | Successful Target | Target Info | [2] | ||
Proto-oncogene c-Ret (RET) | Successful Target | Target Info | [3] | ||
Tyrosine-protein kinase ABL1 (ABL) | Successful Target | Target Info | [4] | ||
Cyclin-dependent kinase 4 (CDK4) | Successful Target | Target Info | [5] | ||
Cyclin-dependent kinase 6 (CDK6) | Successful Target | Target Info | [6] | ||
Platelet-derived growth factor receptor beta (PDGFRB) | Successful Target | Target Info | [2] | ||
Apoptosis regulator Bcl-2 (BCL-2) | Successful Target | Target Info | [7] | ||
Calcitonin receptor (CALCR) | Successful Target | Target Info | [8] | ||
Lipoprotein lipase (LPL) | Successful Target | Target Info | [9] | ||
Succinate-semialdehyde dehydrogenase (ALDH5A1) | Successful Target | Target Info | [10] | ||
Vascular endothelial growth factor A (VEGFA) | Successful Target | Target Info | [11] | ||
Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) | Successful Target | Target Info | [12] | ||
Aryl hydrocarbon receptor (AHR) | Successful Target | Target Info | [1] | ||
Glycogen synthase kinase-3 beta (GSK-3B) | Clinical trial Target | Target Info | [13] | ||
Cyclin-dependent kinase 2 (CDK2) | Clinical trial Target | Target Info | [5] | ||
RAC-gamma serine/threonine-protein kinase (AKT3) | Successful Target | Target Info | [14] | ||
DNA [cytosine-5]-methyltransferase 1 (DNMT1) | Clinical trial Target | Target Info | [15] | ||
DNA [cytosine-5]-methyltransferase 3B (DNMT3B) | Clinical trial Target | Target Info | [16] | ||
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) | Clinical trial Target | Target Info | [17] | ||
Integrin beta-1 (ITGB1) | Clinical trial Target | Target Info | [18] | ||
Beta-secretase 1 (BACE1) | Clinical trial Target | Target Info | [19] | ||
CDC7-related kinase (CDC7) | Clinical trial Target | Target Info | [20] | ||
Dickkopf-related protein 1 (DKK1) | Clinical trial Target | Target Info | [21] | ||
G1/S-specific cyclin-D1 (CCND1) | Clinical trial Target | Target Info | [5] | ||
B7 homolog 3 (CD276) | Clinical trial Target | Target Info | [22] | ||
Collagen I (COL1A2) | Clinical trial Target | Target Info | [23] | ||
Interferon alpha/beta receptor 1 (IFNAR1) | Clinical trial Target | Target Info | [24] | ||
Mucin-1 (MUC1) | Clinical trial Target | Target Info | [25] | ||
Transforming growth factor beta 3 (TGFB3) | Clinical trial Target | Target Info | [3] | ||
S100 calcium-binding protein B (S100B) | Clinical trial Target | Target Info | [26] | ||
Insulin-like growth factor-I (IGF1) | Clinical trial Target | Target Info | [27] | ||
Kruppel like factor 4 (KLF4) | Clinical trial Target | Target Info | [28] | ||
DNA [cytosine-5]-methyltransferase 3A (DNMT3A) | Patented-recorded Target | Target Info | [16] | ||
Glutamate decarboxylase (GLUL) | Discontinued Target | Target Info | [29] | ||
Phosphatase and tensin homolog (PTEN) | Literature-reported Target | Target Info | [30] | ||
Proto-oncogene c-Myc (MYC) | Literature-reported Target | Target Info | [31] | ||
RAC-beta serine/threonine-protein kinase (AKT2) | Literature-reported Target | Target Info | [32] | ||
Lysine-specific demethylase 5B (KDM5B) | Literature-reported Target | Target Info | [33] | ||
Ribonuclease L (RNASEL) | Literature-reported Target | Target Info | [34] | ||
Zinc finger protein A20 (TNFAIP3) | Literature-reported Target | Target Info | [35] | ||
Dystroglycan (DAG1) | Literature-reported Target | Target Info | [3] | ||
Fibrinogen (FGG) | Literature-reported Target | Target Info | [36] | ||
Lysyl oxidase (LOX) | Literature-reported Target | Target Info | [2] | ||
Normal cross-reacting antigen (CD66c) | Clinical trial Target | Target Info | [37] | ||
Protein phosphatase 1D (PPM1D) | Literature-reported Target | Target Info | [38] | ||
Direct IAP-binding protein with low pI (DIABLO) | Literature-reported Target | Target Info | [3] | ||
Integrin alpha-11 (ITGA11) | Literature-reported Target | Target Info | [39] | ||
Integrin alpha-6 (ITGA6) | Literature-reported Target | Target Info | [40] | ||
Laminin gamma-2 subunit (LAMC2) | Literature-reported Target | Target Info | [41] | ||
N-myc proto-oncogene protein (MYCN) | Literature-reported Target | Target Info | [42] | ||
Osteonectin (SPARC) | Literature-reported Target | Target Info | [43] | ||
Super conserved receptor brain 2 (GPR85) | Literature-reported Target | Target Info | [8] | ||
Protein(s) Regulated by This miRNA | A disintegrin and metalloproteinase with thrombospondin motifs 9 | Regulated Protein | [39] | ||
Apoptosis-stimulating of p53 protein 1 | Regulated Protein | [45] | |||
Autophagy-related protein 9A | Regulated Protein | [46] | |||
B-cell CLL/lymphoma 7 protein family member A | Regulated Protein | [47] | |||
Beta/gamma crystallin domain-containing protein 1 | Regulated Protein | [48] | |||
Cell division control protein 42 homolog | Regulated Protein | [45] | |||
Claudin-1 | Regulated Protein | [49] | |||
Collagen alpha-1(III) chain | Regulated Protein | [2] | |||
Collagen alpha-1(IV) chain | Regulated Protein | [2] | |||
Collagen alpha-1(X) chain | Regulated Protein | [2] | |||
Collagen alpha-2(IV) chain | Regulated Protein | [51] | |||
Collagen alpha-2(V) chain | Regulated Protein | [2] | |||
Complement C1q tumor necrosis factor-related protein 6 | Regulated Protein | [52] | |||
Complement component C1q receptor | Regulated Protein | [8] | |||
Cyclin-T2 | Regulated Protein | [54] | |||
Cytochrome P450 2C19 | Regulated Protein | [55] | |||
Cytoplasmic polyadenylation element-binding protein 3 | Regulated Protein | [56] | |||
Cytoplasmic polyadenylation element-binding protein 4 | Regulated Protein | [56] | |||
Desmocollin-2 | Regulated Protein | [48] | |||
Disintegrin and metalloproteinase domain-containing protein 12 | Regulated Protein | [57] | |||
E3 ubiquitin-protein ligase AMFR | Regulated Protein | [48] | |||
E3 ubiquitin-protein ligase TRIM63 | Regulated Protein | [3] | |||
E3 ubiquitin-protein ligase TRIM68 | Regulated Protein | [59] | |||
Elastin | Regulated Protein | [60] | |||
Epithelial membrane protein 1 | Regulated Protein | [48] | |||
Fibrillin-1 | Regulated Protein | [2] | |||
Fibrinogen alpha chain | Regulated Protein | [36] | |||
Fibrinogen beta chain | Regulated Protein | [36] | |||
Forkhead box protein O3 | Regulated Protein | [62] | |||
G/T mismatch-specific thymine DNA glycosylase | Regulated Protein | [63] | |||
G1/S-specific cyclin-D2 | Regulated Protein | [64] | |||
GTP-binding nuclear protein Ran | Regulated Protein | [65] | |||
Histone-lysine N-methyltransferase SETDB1 | Regulated Protein | [66] | |||
HMG box-containing protein 1 | Regulated Protein | [67] | |||
Inter-alpha-trypsin inhibitor heavy chain H5 | Regulated Protein | [47] | |||
Kremen protein 2 | Regulated Protein | [21] | |||
Max dimerization protein 1 | Regulated Protein | [48] | |||
Methylcytosine dioxygenase TET1 | Regulated Protein | [69] | |||
Methylcytosine dioxygenase TET2 | Regulated Protein | [70] | |||
Methylcytosine dioxygenase TET3 | Regulated Protein | [70] | |||
N-myc-interactor | Regulated Protein | [71] | |||
Neuron navigator 3 | Regulated Protein | [72] | |||
Nuclear autoantigenic sperm protein | Regulated Protein | [73] | |||
Nuclear factor 1 A-type | Regulated Protein | [8] | |||
Nuclear factor 1 A-type | Regulated Protein | [74] | |||
Period circadian protein homolog 1 | Regulated Protein | [75] | |||
Peroxidasin homolog | Regulated Protein | [47] | |||
Phosphatase and actin regulator 2 | Regulated Protein | [48] | |||
Phosphatidylinositol 3-kinase regulatory subunit alpha | Regulated Protein | [76] | |||
Protein quaking | Regulated Protein | [77] | |||
RAS guanyl-releasing protein 1 | Regulated Protein | [23] | |||
Roundabout homolog 1 | Regulated Protein | [79] | |||
Secreted frizzled-related protein 2 | Regulated Protein | [21] | |||
Serine/threonine-protein kinase RIO3 | Regulated Protein | [48] | |||
Serpin B9 | Regulated Protein | [80] | |||
Serpin H1 | Regulated Protein | [81] | |||
SLIT-ROBO Rho GTPase-activating protein 2 | Regulated Protein | [8] | |||
Solute carrier family 22 member 7 | Regulated Protein | [10] | |||
Sorting nexin-24 | Regulated Protein | [48] | |||
Suppressor APC domain-containing protein 2 | Regulated Protein | [83] | |||
TNF receptor-associated factor 4 | Regulated Protein | [84] | |||
Transcription factor EB | Regulated Protein | [46] | |||
Tubulin beta-2A chain | Regulated Protein | [48] | |||
Voltage-dependent anion-selective channel protein 1 | Regulated Protein | [85] | |||
WD repeat-containing protein 26 | Regulated Protein | [48] | |||
Zinc finger protein 823 | Regulated Protein | [86] | |||
References | |||||
REF 1 | Inhibition of miR-29 has a significant lipid-lowering benefit through suppression of lipogenic programs in liver. Sci Rep. 2015 Aug 6;5:12911. | ||||
REF 2 | A miRNA-regulatory network explains how dysregulated miRNAs perturb oncogenic processes across diverse cancers. Genome Res. 2012 Nov;22(11):2302-14. | ||||
REF 3 | Dysregulation and cellular mislocalization of specific miRNAs in myotonic dystrophy type 1. Neuromuscul Disord. 2011 Feb;21(2):81-8. | ||||
REF 4 | miR-29b suppresses CML cell proliferation and induces apoptosis via regulation of BCR/ABL1 protein. Exp Cell Res. 2013 May 1;319(8):1094-101. | ||||
REF 5 | Reduced miR-29a-3p expression is linked to the cell proliferation and cell migration in gastric cancer. World J Surg Oncol. 2015 Mar 12;13:101. | ||||
REF 6 | Physiological identification of human transcripts translationally regulated by a specific microRNA. Hum Mol Genet. 2005 Dec 15;14(24):3813-21. | ||||
REF 7 | Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology. 2010 Mar;51(3):836-45. | ||||
REF 8 | miR-29 promotes murine osteoclastogenesis by regulating osteoclast commitment and migration. J Biol Chem. 2013 Nov 15;288(46):33347-60. | ||||
REF 9 | MicroRNA-29a regulates pro-inflammatory cytokine secretion and scavenger receptor expression by targeting LPL in oxLDL-stimulated dendritic cells. FEBS Lett. 2011 Feb 18;585(4):657-63. | ||||
REF 10 | Modulation of ALDH5A1 and SLC22A7 by microRNA hsa-miR-29a-3p in human liver cells. Biochem Pharmacol. 2015 Dec 15;98(4):671-80. | ||||
REF 11 | Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell. 2010 Apr 2;141(1):129-41. | ||||
REF 12 | Underexpression of CACNA1C Caused by Overexpression of microRNA-29a Underlies the Pathogenesis of Atrial Fibrillation. Med Sci Monit. 2016 Jun 24;22:2175-81. | ||||
REF 13 | MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3 signaling pathway. Gene. 2016 Nov 15;593(1):84-90. | ||||
REF 14 | MicroRNA-29B (mir-29b) regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3. Oncotarget. 2015 Dec 1;6(38):40799-814. | ||||
REF 15 | Involvement of miRNA-29a in epigenetic regulation of transforming growth factor--induced epithelial-mesenchymal transition in hepatocellular carcinoma. Hepatol Res. 2014 Aug;44(8):907-19. | ||||
REF 16 | MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15805-10. | ||||
REF 17 | mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene. 2007 Sep 13;26(42):6133-40. | ||||
REF 18 | hTERT mediates gastric cancer metastasis partially through the indirect targeting of ITGB1 by microRNA-29a. Sci Rep. 2016 Feb 23;6:21955. | ||||
REF 19 | The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci. 2008 Jan 30;28(5):1213-23. | ||||
REF 20 | MicroRNA-29a regulates the benzo[a]pyrene dihydrodiol epoxide-induced DNA damage response through Cdc7 kinase in lung cancer cells. Oncogenesis. 2013 Jul 22;2:e57. | ||||
REF 21 | miR-29 modulates Wnt signaling in human osteoblasts through a positive feedback loop. J Biol Chem. 2010 Aug 13;285(33):25221-31. | ||||
REF 22 | MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res. 2009 Aug 1;69(15):6275-81. | ||||
REF 23 | Protective role of microRNA-29a in denatured dermis and skin fibroblast cells after thermal injury. Biol Open. 2016 Jan 21;5(3):211-9. | ||||
REF 24 | Respiratory syncytial virus non-structural protein 1 facilitates virus replication through miR-29a-mediated inhibition of interferon- receptor. Biochem Biophys Res Commun. 2016 Sep 23;478(3):1436-41. | ||||
REF 25 | Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells. Biochim Biophys Acta. 2015 Oct;1853(10 Pt A):2392-403. | ||||
REF 26 | Human cellular microRNA hsa-miR-29a interferes with viral nef protein expression and HIV-1 replication. Retrovirology. 2008 Dec 23;5:117. | ||||
REF 27 | An androgen receptor-microrna-29a regulatory circuitry in mouse epididymis. J Biol Chem. 2013 Oct 11;288(41):29369-81. | ||||
REF 28 | Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. Oncogene. 2013 May 16;32(20):2555-64. | ||||
REF 29 | MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome. Gut. 2010 Jun;59(6):775-84. | ||||
REF 30 | Prediction of mammalian microRNA targets. Cell. 2003 Dec 26;115(7):787-98. | ||||
REF 31 | MiRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc. Oncotarget. 2016 Feb 9;7(6):7149-60. | ||||
REF 32 | The role, mechanism and potentially therapeutic application of microRNA-29 family in acute myeloid leukemia. Cell Death Differ. 2014 Jan;21(1):100-12. | ||||
REF 33 | MiR-29a suppresses prostate cell proliferation and induces apoptosis via KDM5B protein regulation. Int J Clin Exp Med. 2015 Apr 15;8(4):5329-39. | ||||
REF 34 | Regulation of human RNase-L by the miR-29 family reveals a novel oncogenic role in chronic myelogenous leukemia. J Interferon Cytokine Res. 2013 Jan;33(1):34-42. | ||||
REF 35 | miR-29c targets TNFAIP3, inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma. Biochem Biophys Res Commun. 2011 Aug 5;411(3):586-92. | ||||
REF 36 | Regulation of fibrinogen production by microRNAs. Blood. 2010 Oct 7;116(14):2608-15. | ||||
REF 37 | MicroRNA-29a suppresses the growth, migration, and invasion of lung adenocarcinoma cells by targeting carcinoembryonic antigen-related cell adhesion molecule 6. FEBS Lett. 2014 Oct 16;588(20):3744-50. | ||||
REF 38 | microRNA expression alteration after arsenic trioxide treatment in HepG-2 cells. J Gastroenterol Hepatol. 2011 Jan;26(1):186-93. | ||||
REF 39 | miR-29 is a major regulator of genes associated with pulmonary fibrosis. Am J Respir Cell Mol Biol. 2011 Aug;45(2):287-94. | ||||
REF 40 | Tumour-suppressive microRNA-29s inhibit cancer cell migration and invasion by targeting laminin-integrin signalling in head and neck squamous cell carcinoma. Br J Cancer. 2013 Nov 12;109(10):2636-45. | ||||
REF 41 | A combined computational-experimental approach predicts human microRNA targets. Genes Dev. 2004 May 15;18(10):1165-78. | ||||
REF 42 | Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Br J Cancer. 2011 Jul 12;105(2):296-303. | ||||
REF 43 | MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5874-8. | ||||
REF 44 | miR-29 is a major regulator of genes associated with pulmonary fibrosis. Am J Respir Cell Mol Biol. 2011 Aug;45(2):287-94. | ||||
REF 45 | miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42.Nat Struct Mol Biol. 2009 Jan;16(1):23-9. | ||||
REF 46 | Novel role of miR-29a in pancreatic cancer autophagy and its therapeutic potential.Oncotarget. 2016 Nov 1;7(44):71635-71650. | ||||
REF 47 | Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression.Proc Natl Acad Sci U S A. 2010 Jul 6;107(27):12210-5. | ||||
REF 48 | MicroRNA profiling in mucosal biopsies of eosinophilic esophagitis patients pre and post treatment with steroids and relationship with mRNA targets. PLoS One. 2012;7(7):e40676. | ||||
REF 49 | miR-29a suppresses growth and migration of hepatocellular carcinoma by regulating CLDN1.Biochem Biophys Res Commun. 2017 May 6;486(3):732-737. | ||||
REF 50 | A miRNA-regulatory network explains how dysregulated miRNAs perturb oncogenic processes across diverse cancers. Genome Res. 2012 Nov;22(11):2302-14. | ||||
REF 51 | High glucose down-regulates miR-29a to increase collagen IV production in HK-2 cells.FEBS Lett. 2010 Feb 19;584(4):811-6. | ||||
REF 52 | A combined approach identifies three mRNAs that are down-regulated by microRNA-29b and promote invasion ability in the breast cancer cell line MCF-7. J Cancer Res Clin Oncol. 2012 Dec;138(12):2127-36. | ||||
REF 53 | miR-29 promotes murine osteoclastogenesis by regulating osteoclast commitment and migration. J Biol Chem. 2013 Nov 15;288(46):33347-60. | ||||
REF 54 | MicroRNA-29a and microRNA-142-3p are regulators of myeloid differentiation and acute myeloid leukemia. Blood. 2012 May 24;119(21):4992-5004. | ||||
REF 55 | MicroRNA hsa-miR-29a-3p modulates CYP2C19 in human liver cells.Biochem Pharmacol. 2015 Nov 1;98(1):215-23. | ||||
REF 56 | CPEB2, CPEB3 and CPEB4 are coordinately regulated by miRNAs recognizing conserved binding sites in paralog positions of their 3'-UTRs.Nucleic Acids Res. 2010 Nov;38(21):7698-710. | ||||
REF 57 | ADAM12-L is a direct target of the miR-29 and miR-200 families in breast cancer.BMC Cancer. 2015 Mar 4;15:93. | ||||
REF 58 | Dysregulation and cellular mislocalization of specific miRNAs in myotonic dystrophy type 1. Neuromuscul Disord. 2011 Feb;21(2):81-8. | ||||
REF 59 | Epigenetic deregulation of miR-29a and miR-1256 by isoflavone contributes to the inhibition of prostate cancer cell growth and invasion.Epigenetics. 2012 Aug;7(8):940-9. | ||||
REF 60 | MiR-29-mediated elastin down-regulation contributes to inorganic phosphorus-induced osteoblastic differentiation in vascular smooth muscle cells.Genes Cells. 2015 Dec;20(12):1077-87. | ||||
REF 61 | Regulation of fibrinogen production by microRNAs. Blood. 2010 Oct 7;116(14):2608-15. | ||||
REF 62 | FOXO3A regulation by miRNA-29a Controls chondrogenic differentiation of mesenchymal stem cells and cartilage formation.Stem Cells Dev. 2014 Jun 1;23(11):1195-205. | ||||
REF 63 | miR-29 represses the activities of DNA methyltransferases and DNA demethylases.Int J Mol Sci. 2013 Jul 12;14(7):14647-58. | ||||
REF 64 | Characterization of microRNA-29 family expression and investigation of their mechanistic roles in gastric cancer. Carcinogenesis. 2014 Feb;35(2):497-506. | ||||
REF 65 | MiRNA-29a regulates the expression of numerous proteins and reduces the invasiveness and proliferation of human carcinoma cell lines.Eur J Cancer. 2009 Nov;45(17):3104-18. | ||||
REF 66 | Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis.Hepatology. 2016 Feb;63(2):474-87. | ||||
REF 67 | MiR-29a modulates the angiogenic properties of human endothelial cells.Biochem Biophys Res Commun. 2013 Apr 26;434(1):143-9. | ||||
REF 68 | miR-29 modulates Wnt signaling in human osteoblasts through a positive feedback loop. J Biol Chem. 2010 Aug 13;285(33):25221-31. | ||||
REF 69 | MicroRNA 29b functions in acute myeloid leukemia. Blood. 2009 Dec 17;114(26):5331-41. | ||||
REF 70 | Ten-eleven translocation (Tet) and thymine DNA glycosylase (TDG), components of the demethylation pathway, are direct targets of miRNA-29a.Biochem Biophys Res Commun. 2013 Aug 2;437(3):368-73. | ||||
REF 71 | microRNA-29 negatively regulates EMT regulator N-myc interactor in breast cancer.Mol Cancer. 2014 Aug 29;13:200. | ||||
REF 72 | Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3.Neuropathol Appl Neurobiol. 2010 Jun;36(4):320-30. | ||||
REF 73 | Interplay between HIV-1 infection and host microRNAs. Nucleic Acids Res. 2012 Mar;40(5):2181-96. | ||||
REF 74 | miR-29a activates Hes1 by targeting Nfia in esophageal carcinoma cell line TE-1. Oncol Lett. 2015 Jan;9(1):96-102. | ||||
REF 75 | MiR-29a/b/c regulate human circadian gene hPER1 expression by targeting its 3'UTR.Acta Biochim Biophys Sin (Shanghai). 2014 Apr;46(4):313-7. | ||||
REF 76 | miR-29a levels are elevated in the db/db mice liver and its overexpression leads to attenuation of insulin action on PEPCK gene expression in HepG2 cells.Mol Cell Endocrinol. 2011 Jan 30;332(1-2):125-33. | ||||
REF 77 | miR-29a promotes scavenger receptor A expression by targeting QKI (quaking) during monocyte-macrophage differentiation.Biochem Biophys Res Commun. 2015 Aug 14;464(1):1-6. | ||||
REF 78 | Protective role of microRNA-29a in denatured dermis and skin fibroblast cells after thermal injury. Biol Open. 2016 Jan 21;5(3):211-9. | ||||
REF 79 | MicroRNA-29a inhibits cell migration and invasion via targeting Roundabout homolog 1 in gastric cancer cells.Mol Med Rep. 2015 Sep;12(3):3944-3950. | ||||
REF 80 | Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia. Haematologica. 2011 Dec;96(12):1783-91. | ||||
REF 81 | Tumor-suppressive microRNA-29a inhibits cancer cell migration and invasion via targeting HSP47 in cervical squamous cell carcinoma.Int J Oncol. 2013 Dec;43(6):1855-63. | ||||
REF 82 | Modulation of ALDH5A1 and SLC22A7 by microRNA hsa-miR-29a-3p in human liver cells. Biochem Pharmacol. 2015 Dec 15;98(4):671-80. | ||||
REF 83 | MiR-29a inhibits cell proliferation and induces cell cycle arrest through the downregulation of p42.3 in human gastric cancer.PLoS One. 2011;6(10):e25872. | ||||
REF 84 | Tumor necrosis factor receptor associated factor-4: an adapter protein overexpressed in metastatic prostate cancer is regulated by microRNA-29a.Oncol Rep. 2013 Dec;30(6):2963-8. | ||||
REF 85 | Identification of novel targets for miR-29a using miRNA proteomics.PLoS One. 2012;7(8):e43243. | ||||
REF 86 | miR-29a inhibition normalizes HuR over-expression and aberrant AU-rich mRNA stability in invasive cancer.J Pathol. 2013 May;230(1):28-38. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.